content_image/209006.jpg content_image/209009.jpg content_image/209012.jpg
BMS announced the discontinued development of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor that was in Phase II development for the treatment of the hepatitis C virus infection on August 23, 2012. The decision was made in the interest of patient safety, based on a rapid, thorough and ongoing assessment of patients in a Phase II study that was voluntarily suspended on August 1, 2012. BMS acquired BMS-986094 with its acquisition of Inhibitex in February 2012. As a result of the termination of this development program, a $1,830 million pre-tax impairment charge was recognized for the IPRD intangible asset. 

$^{ }$An impairment charge of $120 million was recognized in 2012 related to a partial write-down to fair value of developed technology costs related to a non-key product ( Recothrom ) acquired in the acquisition of ZymoGenetics. The developed technology impairment charge resulted from continued competitive pricing pressures. 

## $^{ }$Note 14 ACCRUED EXPENSES 

Accrued expenses include: 

<img src='content_image/209006.jpg'>

## $^{ }$Note 15 SALES REBATES AND RETURN ACCRUALS 

$^{ }$Reductions to trade receivables and accrued rebates and returns liabilities are as follows: 

<img src='content_image/209009.jpg'>

## $^{ }$Note 16 DEFERRED INCOME 

$^{ }$Deferred income includes: 

<img src='content_image/209012.jpg'>

$^{ }$Upfront, milestone and other licensing receipts are amortized over the expected life of the product. See Note 3 “Alliances and Collaborations” for information pertaining to revenue recognition and other transactions including $3.5 billion of proceeds received from AstraZeneca related to the Amylin collaboration during the 2012. Deferred gains on several sale-leaseback transactions are amortized over the remaining lease terms of the related facilities through 2018. Deferred income amortization was $308 million in 2012, $173 million in 2011 and $137 million in 2010. 

